Ventyx Biosciences Inc. (NASDAQ: VTYX) stock jumped 2.11% on Monday to $34.87 against a previous-day closing price of $34.15. With 1.56 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.58 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $36.69 whereas the lowest price it dropped to was $33.66. The 52-week range on VTYX shows that it touched its highest point at $41.29 and its lowest point at $9.50 during that stretch. It currently has a 1-year price target of $51.45.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VTYX was up-trending over the past week, with a rise of 0.29%, but this was up by 10.45% over a month. Three-month performance surged to 34.69% while six-month performance rose 133.71%. The stock gained 141.48% in the past year, while it has gained 6.34% so far this year. A look at the trailing 12-month EPS for VTYX yields -1.78 with Next year EPS estimates of -2.45. For the next quarter, that number is -0.60. This implies an EPS growth rate of -193.90% for this year and -20.10% for next year.
Float and Shares Shorts:
At present, 51.67 million VTYX shares are outstanding with a float of 50.91 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.99 million, which was 7.06% higher than short shares on Sep 14, 2022. In addition to Dr. Sheila K. Gujrathi M.D. as the firm’s Exec. Chair, Dr. Raju S. Mohan Ph.D. serves as its Founder, CEO & Director.
Through their ownership of 92.73% of VTYX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 37.77% of VTYX, in contrast to 29.08% held by mutual funds. Shares owned by individuals account for 21.89%. As the largest shareholder in VTYX with 6.13% of the stake, Citadel Advisors LLC holds 3,471,164 shares worth 3,471,164. A second-largest stockholder of VTYX, Third Point LLC, holds 2,252,432 shares, controlling over 3.98% of the firm’s shares. Fidelity Management & Research Co is the third largest shareholder in VTYX, holding 1,766,272 shares or 3.12% stake. With a 3.73% stake in VTYX, the American Funds Small Cap World Fu is the largest stakeholder. A total of 2,114,744 shares are owned by the mutual fund manager. The T Rowe Price New Horizons Fund, which owns about 1.71% of VTYX stock, is the second-largest Mutual Fund holder. It holds 968,296 shares valued at 31.75 million. Vanguard Total Stock Market Index holds 1.53% of the stake in VTYX, owning 868,284 shares worth 28.47 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VTYX since 11 analysts follow the stock currently. There are 11 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VTYX analysts setting a high price target of $63.00 and a low target of $35.00, the average target price over the next 12 months is $51.45. Based on these targets, VTYX could surge 80.67% to reach the target high and rise by 0.37% to reach the target low. Reaching the average price target will result in a growth of 47.55% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VTYX will report FY 2022 earnings on 03/20/2024. Analysts have provided yearly estimates in a range of -$1.72 being high and -$2.13 being low. For VTYX, this leads to a yearly average estimate of -$1.98. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Ventyx Biosciences Inc. surprised analysts by -$0.15 when it reported -$0.59 EPS against a consensus estimate of -$0.44. The surprise factor in the prior quarter was $0.07. Based on analyst estimates, the high estimate for the next quarter is -$0.51 and the low estimate is -$0.69. The average estimate for the next quarter is thus -$0.59.
Summary of Insider Activity:
Insiders traded VTYX stock several times over the past three months with 8 Buys and 26 Sells. In these transactions, 254,762 shares were bought while 8,513,633 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 26 over the past year. The total number of shares bought during that period was 424,123 while 8,513,633 shares were sold.